IL163648A0 - B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist - Google Patents

B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist

Info

Publication number
IL163648A0
IL163648A0 IL16364803A IL16364803A IL163648A0 IL 163648 A0 IL163648 A0 IL 163648A0 IL 16364803 A IL16364803 A IL 16364803A IL 16364803 A IL16364803 A IL 16364803A IL 163648 A0 IL163648 A0 IL 163648A0
Authority
IL
Israel
Prior art keywords
ylmethylü
asccr3
aminophenylüacetamide
methylsulphonyl
difluorobenzyl
Prior art date
Application number
IL16364803A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL163648A0 publication Critical patent/IL163648A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL16364803A 2002-03-28 2003-03-27 B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist IL163648A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds
PCT/EP2003/003339 WO2003082291A1 (en) 2002-03-28 2003-03-27 N-{´ (2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions

Publications (1)

Publication Number Publication Date
IL163648A0 true IL163648A0 (en) 2005-12-18

Family

ID=9933998

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16364803A IL163648A0 (en) 2002-03-28 2003-03-27 B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist

Country Status (22)

Country Link
US (1) US20060058299A1 (enExample)
EP (1) EP1487453B1 (enExample)
JP (1) JP4490110B2 (enExample)
KR (1) KR20040095347A (enExample)
CN (1) CN1642553A (enExample)
AR (1) AR039177A1 (enExample)
AT (1) ATE454892T1 (enExample)
AU (1) AU2003216905A1 (enExample)
BR (1) BR0308719A (enExample)
CA (1) CA2479910A1 (enExample)
DE (1) DE60330952D1 (enExample)
ES (1) ES2339436T3 (enExample)
GB (1) GB0207449D0 (enExample)
IL (1) IL163648A0 (enExample)
IS (1) IS7415A (enExample)
MX (1) MXPA04009458A (enExample)
NO (1) NO20044098L (enExample)
PL (1) PL372930A1 (enExample)
RU (1) RU2004126145A (enExample)
TW (1) TW200400823A (enExample)
WO (1) WO2003082291A1 (enExample)
ZA (1) ZA200406990B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028530A1 (en) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
JP2009501792A (ja) * 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体のモジュレーターとしてのｎ−ベンジル−モルホリン誘導体
HUP0500877A2 (en) * 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
HUP0500886A2 (en) * 2005-09-23 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use
WO2007034252A1 (en) * 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as ccr3 receptor liquids
HUP0800478A2 (en) * 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
WO2013079696A1 (en) * 2011-12-01 2013-06-06 Glaxo Group Limited Methods of treatment and prevention of eye diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562929A (en) * 1979-06-21 1981-01-13 Sumitomo Chem Co Ltd Preparation of optically active cyclopentenolone
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPH01117882A (ja) * 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JPH03291274A (ja) * 1990-04-09 1991-12-20 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
TW223629B (enExample) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU2056800A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
ATE254620T1 (de) * 1999-09-14 2003-12-15 Aventis Pharma Inc Unsubstituierte ethyl- und propylderivate von phenoxythienoisoxazolen als d4 antagonisten
CZ20031195A3 (cs) * 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
ES2275729T3 (es) * 2000-09-29 2007-06-16 Glaxo Group Limited Compuestos utiles en el tratamiento de enfermedades inflamatorias.

Also Published As

Publication number Publication date
CN1642553A (zh) 2005-07-20
RU2004126145A (ru) 2005-06-27
CA2479910A1 (en) 2003-10-09
KR20040095347A (ko) 2004-11-12
ATE454892T1 (de) 2010-01-15
NO20044098L (no) 2004-10-04
IS7415A (is) 2004-08-19
JP4490110B2 (ja) 2010-06-23
GB0207449D0 (en) 2002-05-08
PL372930A1 (en) 2005-08-08
DE60330952D1 (de) 2010-03-04
ZA200406990B (en) 2005-11-08
BR0308719A (pt) 2005-01-04
ES2339436T3 (es) 2010-05-20
AU2003216905A1 (en) 2003-10-13
JP2005525390A (ja) 2005-08-25
EP1487453A1 (en) 2004-12-22
EP1487453B1 (en) 2010-01-13
AR039177A1 (es) 2005-02-09
US20060058299A1 (en) 2006-03-16
WO2003082291A1 (en) 2003-10-09
TW200400823A (en) 2004-01-16
MXPA04009458A (es) 2005-07-27

Similar Documents

Publication Publication Date Title
IL163817A0 (en) 2,4-Diaminopyrimidine
SI1555267T1 (sl) 2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
IL165841A0 (en) Mchir antagonists
GB0115517D0 (en) Novel antidiabetic agents
IL164608A0 (en) 2-(2,6-Dichlorophenyl)-diarylimidazoles
AU2003249187A8 (en) On chip network
SI1699795T1 (sl) Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
AU2003206028A1 (en) Antidiabetic agents
AU2002341834A1 (en) Antagonists
AU2003268304A8 (en) Toolholder
HU0303119D0 (en) Chisel
GB0211257D0 (en) Novel heterocycles
PL374833A1 (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor
IL163939A0 (en) Nk1 antagonists
EP1411070A4 (en) COPOLYMER SEQUENCE
AU2003236247A1 (en) Bombesin antagonists
AU2003300883A8 (en) Substituted 1-benzoyl-3-cyano-pyrrolo(1,2-a)quinolines
SG110051A1 (en) Propylene-ethylene block copolymer
PL362838A1 (en) Somatostatin antagonists
IL163648A0 (en) B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist
GB0217347D0 (en) Novel albumins
GB0209989D0 (en) Novel heterocycles
AU2003215804A1 (en) Antidiabetic agents
AU2003215803A1 (en) Antidiabetic agents
GB2400848B (en) Novel anti-fungal agents